Loading......
IMFINZI DOSING
Dosing and method of administration
INDIVIDUAL WEIGHT-BASED DOSING1
- IMFINZI is supplied as single-use vials that contain either 500 mg/10 mL or 120 mg/2.4 mL.1 Refer to the IMFINZI SmPC for further information on storage, dilution, and administration instructions
- Treatment must be initiated and supervised by a physician experienced in the treatment of cancer1
- Infusion-related reactions with IMFINZI were observed in 1.9% of patients in the PACIFIC study1
It is recommended to continue treatment for clinically stable patients with initial evidence of disease progression until disease progression is confirmed.1
Continue treatment with IMFINZI for 12 months in the absence of disease progression or unacceptable toxicity1
PREVIOUS
View the safety and tolerability
profile for IMFINZI
NEXT
Which of your patients could
benefit from IMFINZI?